please help improve it or discuss these issues on the talk page . learn how and when to remove these template messages this article has an unclear citation style . the references used may be made clearer with a different or consistent style of citation footnoting or external linking . august 2013 learn how and when to remove this template message this article is an orphan as no other articles link to it . please introduce links to this page from related articles ; try the find link tool for suggestions . july 2013 learn how and when to remove this template message catabasis pharmaceuticals type public traded as nasdaq catb industry pharmaceuticals headquarters cambridge massachusetts key people jill c. milne ph.d. co founder and ceo michael jirousek ph.d. co founder and cso chris thomajan cfo joanne m. donovan m.d. ph.d. cmo michael curtis ph.d. svp product development and regulatory affairs henry rath m.b.a. vp business development products orally delivered pharmaceuticals number of employees 34 june 2015 website www.catabasis.com catabasis pharmaceuticals founded in 2008 and based in cambridge mass . is a clinical stage biopharmaceutical company developing bi functional small molecules for treatment of dyslipidemias and inflammatory diseases . the company s drug development programs are based on the principles of pathway pharmacology to treat diseases by modulating more than one target in a disease pathway simultaneously . 1 catabasis uses a proprietary linker technology to conjugate two drugs that act on different nodes of a disease pathway with the intent of improving safety and efficacy of the two components . the conjugate is designed to keep the linked components inactive in plasma until they are cleaved by a specific class of intracellular enzymes releasing both bioactives within the cells of target tissues . catabasis has two programs in clinical development . cat 2003 a conjugate of the b vitamin niacin and the omega 3 fatty acid eicosapentaenoic acid epa is designed to treat severe hypertriglyceridemia and other lipid disorders and is currently in clinical testing . 2 cat 1004 edasalonexent a conjugate of the omega 3 fatty acid docosahexaenoic acid dha and salicylate has completed phase 1 testing ; 3 the drug is being developed for the treatment of inflammatory diseases such as inflammatory bowel disease and duchenne muscular dystrophy . in the phase 1 study results showed that cat 1004 was safe and well tolerated and that the linker technology allowed the active components to inhibit the nf kb pathway synergistically ; 4 5 this pathway plays an important role in inflammation . 6 references edit 1hendriks bs . 2010 . functional pathway pharmacology chemical tools pathway knowledge and mechanistic model based interpretation of experimental data . current opinion in chemical biology 14 4 489 97 . doi 10.1016 j.cbpa .2010.06.167 . 2clinicaltrial . gov a single and multiple ascending dose study to assess the safety pharmacokinetics and pharmacodynamics of cat 2003 http clinicaltrials.gov ct2 show nct01725594 term cat 2003 & rank 1 3clinicaltrial . gov a multiple ascending dose study of cat 1004 in patients with type 2 diabetes http clinicaltrials.gov ct2 show nct01511900 term cat 1004 & rank 1 safety tolerability and pharmacokinetic study of cat 1004 in healthy adult volunteers http clinicaltrials.gov ct2 show nct01440166 term cat 1004 & rank 2 a study of cat 1004 biomarkers in healthy subjects http clinicaltrials.gov ct2 showqaq nct01670773 term cat 1004 & rank 3 4bioflash mass high tech catabasis sees positive phase 1 data 2 11 13 http www.bizjournals.com boston blog bioflash 2013 02 catabasis sees positive phase 1 data.html 5xconomy catabasis passes first trials with anti inflammatory drug 2 11 13 http www.xconomy.com boston 2013 02 11 catabasis passes first trials with anti inflammatory drug 6tieri p termanini a bellavista e salvioli s capri m et al. 2012 . charting the nf b pathway interactome map . plos one 7 3 e32678 . doi 10.1371 journal.pone .0032678 retrieved from https en.wikipedia.org w index.php title catabasis pharmaceuticals & oldid 742534162 categories biopharmaceutical companiescompanies listed on nasdaqpharmaceutical companies established in 2008hidden categories wikipedia references cleanup from august 2013all articles needing references cleanuparticles covered by wikiproject wikify from august 2013all articles covered by wikiproject wikifyorphaned articles from july 2013all orphaned articles navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages add links this page was last modified on 4 october 2016 at 07 58 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view